Coya 302: A Dual Mechanism Biologic Immunotherapy in the Treatment of ALS By Treg Activity to Reduce Inflammation

Time: 1:10 pm
day: Day Two Track B PM


  • Treg dysfunction is a core driver of neurodegeneration in ALS
  • Coya 302 immunotherapy targets adaptive and innate immune pathways in ALS with strong efficacy signal in an open label exposure trial
  • Advancing Coya 302 in a double-blind placebo controlled clinical trial in ALS